TG Therapeutics price to book ratio TGTX

Market value divided by the book value of the company's net assets, since 2012.

Today, Oct 23, 2026: 13.7×
10-year median: 13.7×
Against its 10-year history: 50th; percentile: 0 is its lowest day, 100 its highest
10-year range: 3.4× to 168×
Peer median: 9.2×

TG Therapeutics' price to book ratio is 13.7× as of Oct 23, 2026.

That is above its ten-year median of 13.7×, close to the middle of its last ten years.

Over that time it ranged from 3.4× in Jun 2022 to 168× in May 2023.

The median for 10 large drugmakers of a similar size is 9.2×.

Price to book ratio over time

median 13.7×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	13.7×	6.9×	15.0×
2025	8.0×	8.0×	30.7×
2024	26.4×	12.2×	28.4×
2023	15.7×	9.4×	168×
2022	17.1×	3.4×	17.1×
2021	8.7×	7.2×	41.8×
2020	40.1×	14.1×	53.3×
2019	58.6×	4.6×	58.6×
2018	4.6×	4.0×	18.3×
2017	7.3×	4.1×	21.5×
2016	4.5×	3.5×	6.0×
2015	5.4×	4.9×	11.4×
2014	10.6×	3.2×	12.0×
2013	2.9×	2.5×	20.4×
2012	9.4×	2.9×	9.4×

Against its peers

Companies in Drug Manufacturers - General nearest TG Therapeutics' size, closest first, today.

Company	Price to book ratio
TGTXTG Therapeutics	13.7×
PTGXProtagonist Therapeutics	10.6×
CORTCorcept Therapeutics	13.2×
ALKSAlkermes plc.	4.0×
AMRXAmneal Pharmaceuticals	197×
BMRNBiomarin Pharmaceutical	1.7×
LGNDLigand Pharmaceuticals	6.3×
KNSAKiniksa Pharmaceuticals International	9.2×
JAZZJazz Pharmaceuticals	2.9×
INDVIndivior Pharmaceuticals	n/m
ARQTArcutis Biotherapeutics	17.8×
Peer median	9.2×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on TG Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.